SCHEMBL1364855

SCHEMBL1364855

CCOC(=O)CCCCCl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.59
ALDH1A1 P00352 4/20 0.49
ALOX15 P16050 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
CYP3A4 P08684 1/20 0.49
TSHR P16473 1/20 0.49
HSD17B10 Q99714 1/20 0.49
DGKA P23743 1/20 0.48
GAA P10253 2/20 0.48
MGAM O43451 1/20 0.48
SI P14410 1/20 0.48
MGAM2 Q2M2H8 1/20 0.48
NR1I2 O75469 1/20 0.47
PGR P06401 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
PTGS2 P35354 1/20 0.47
PDE4D Q08499 1/20 0.47
CYP4F2 P78329 1/20 0.46
CYP4A11 Q02928 1/20 0.46
KMT2A Q03164 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1365271 0.98 CYP1A2 (0.57) CYP1A2ALDH1A1ALOX15TDP1CYP3A4
SCHEMBL1363140 0.98 CYP1A2 (0.57) CYP1A2ALDH1A1ALOX15TDP1CYP3A4
SCHEMBL6080088 0.98 CYP1A2 (0.57) CYP1A2ALDH1A1ALOX15TDP1CYP3A4
SCHEMBL1364872 0.98 CYP1A2 (0.57) CYP1A2ALDH1A1ALOX15TDP1CYP3A4
SCHEMBL1366491 0.98 CYP1A2 (0.57) CYP1A2ALDH1A1ALOX15TDP1CYP3A4
SCHEMBL1364893 0.93
SCHEMBL28902452 0.92 DGKA (0.62) CYP1A2ALDH1A1ALOX15TDP1CYP3A4
SCHEMBL5881214 0.89 CYP1A2 (0.57) CYP1A2ALDH1A1ALOX15TDP1CYP3A4
SCHEMBL8570508 0.88 CYP1A2 (0.73) CYP1A2ALDH1A1ALOX15TDP1CYP3A4
SCHEMBL50610 0.88 CYP1A2 (0.73) CYP1A2ALDH1A1ALOX15TDP1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118566384-A Detection method for determining 5-chlorovalerate ethyl ester genotoxic impurities in apixaban in gas chromatography 云鹏医药集团有限公司 2024-08-30 CN claimed
CN-116623020-A Method for extracting and separating rare earth lanthanum and yttrium by utilizing hydrophobic guanidyl ionic liquid 贵州红星电子材料有限公司 2023-08-22 CN claimed
CN-107663170-B Method for preparing besifloxacin intermediate compound 广东东阳光药业有限公司 2020-02-11 CN claimed
CN-118566384-A Detection method for determining 5-chlorovalerate ethyl ester genotoxic impurities in apixaban in gas chromatography 云鹏医药集团有限公司 2024-08-30 CN disclosed
CN-118566397-A Method for determining toxic impurities of 5-chlorovalerate in apixaban by derivative mode 云鹏医药集团有限公司 2024-08-30 CN disclosed
US-11958802-B2 Migration-resistant photopolymerization sensitizer KAWASAKI KASEI CHEMICALS LTD. (JP) 2024-04-16 US disclosed
CN-113166036-B Photopolymerizing sensitizers with migration resistance 川崎化成工业株式会社 2023-10-10 CN disclosed
CN-116623020-A Method for extracting and separating rare earth lanthanum and yttrium by utilizing hydrophobic guanidyl ionic liquid 贵州红星电子材料有限公司 2023-08-22 CN disclosed
US-20220106254-A1 MIGRATION-RESISTANT PHOTOPOLYMERIZATION SENSITIZER KAWASAKI KASEI CHEMICALS LTD. (JP) 2022-04-07 US disclosed
CN-113166036-A Photopolymerisable sensitizers having migration resistance 川崎化成工业株式会社 2021-07-23 CN disclosed
WO-2020213442-A1 PHOTOPOLYMERIZABLE COMPOSITION, COATING FILM CONTAINING SAID PHOTOPOLYMERIZABLE COMPOSITION, AND CURING METHOD THEREFOR 川崎化成工業株式会社 2020-10-22 WO disclosed
CN-1026112-C Process of preparing hydroxyalkylxanthines and medicines containing them and uses thereof HOECHST AG (DE) 1994-10-05 CN disclosed
US-4833146-A BRAINS, BLOOD DISORDERS HOECHST AKTIENGESELLSCHAFT (DE) 1989-05-23 US disclosed
CN-86105835-A Preparation method of tertiary hydroxyalkyl xanthines, medicine containing tertiary hydroxyalkyl xanthines and application thereof 1987-01-14 CN disclosed
US-4234744-A Process for the production of aminoacid hydrochlorides/or diaminoacid dihydrochlorides DEUTSCHE GOLD- UND SILBER SCHEIDEANSTALT VORMALS ROESSLER (DE) 1980-11-18 US disclosed
US-4138556-A ANTIBIOTICS, BACTERICIDES SMITHKLINE CORPORATION (US) 1979-02-06 US disclosed
US-4130644-A BACTERICIDE SMITHKLINE CORPORATION (US) 1978-12-19 US disclosed
US-4112088-A BACTERICIDE SMITHKLINE CORPORATION (US) 1978-09-05 US disclosed
US-4067880-A SULFOALKYL-OXADIAZOLE THIOLS SMITHKLINE CORPORATION (US) 1978-01-10 US disclosed
US-4041162-A ANTIBIOTICS, BACTERICIDES SMITHKLINE CORPORATION (US) 1977-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11958802-B2 Migration-resistant photopolymerization sensitizer F12, F10, PCNA CYP1A2 356/4885ALDH1A1 838/4885ALOX15 122/4885
US-20220106254-A1 MIGRATION-RESISTANT PHOTOPOLYMERIZATION SENSITIZER F12, F10, PCNA CYP1A2 356/4885ALDH1A1 838/4885ALOX15 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.